PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
PR Newswire•03/11/2026•07:00 ET
0
Key Highlights
- ➤PTC Therapeutics (PTCT) authorizes up to $500 million in share repurchases
- ➤Repurchases may use open-market, private, accelerated, or other permitted transactions
- ➤CEO cites confidence in growth while preserving flexibility for business development
Expert Statements
Matthew B. Klein, Chief Executive Officer of PTC Therapeutics
“The share repurchase program reflects our deep conviction in the strength of the Company and the prospects for near- and long-term growth”
Matthew B. Klein, Chief Executive Officer of PTC Therapeutics
“We are investing in PTC at a time when our shares provide a compelling opportunity while still maintaining the financial flexibility to support existing programs and pursue potential value creative business development transactions.”
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program PR Newswire
WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company's outstanding shares of common stock, subject to market conditions.
Get started
Create a free account to read the full story.